Cala Health Receives FDA Clearance for Cala ONE Wrist Device

Burlingame, CA – April 26, 2018 – Cala Health announced today that the US Food and Drug Administration (FDA)
has granted a De Novo request for Cala ONE, an individualized prescription neuromodulation therapy for
transient relief of hand tremors in adults with essential tremor (ET). Cala ONE is the first-ever non-invasive,
targeted nerve stimulator for the treatment of ET to receive FDA marketing authorization. Evidence on Cala ONE
was presented as part of a late-breaking emerging science session at the American Academy of Neurology 70th
Annual Meeting in Los Angeles, CA on April 25, 2018 by Rajesh Pahwa, MD, University of Kansas Medical Center.

Categories: In the News